{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"description":"Number of participants with serious adverse events (SAEs). SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.","groups":[{"description":"Bempegaldesleukin 0.006 mg/kg + Nivolumab 4.5 mg/kg administered intravenously every 3 weeks","id":"OG000","title":"Part A: Bempegaldesleukin (0.006 mg/kg)+ Nivolumab (4.5 mg/kg)"},{"description":"Bempegaldesleukin 0.006 mg/kg + Nivolumab 360 mg administered intravenously every 3 weeks","id":"OG001","title":"Part A: Bempegaldesleukin (0.006 mg/kg)+ Nivolumab (360 mg)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All treated participants in Part A","reportingStatus":"POSTED","timeFrame":"From first dose to 30 days after last dose (up to approximately 6 months)","title":"Number of Participants With Serious Adverse Events (SAEs) - Part A","type":"PRIMARY","unitOfMeasure":"Participants"}